Development and characterization of CV6-168, a novel and selective dUTPase inhibitor that enhances the antitumour efficacy of TS-targeted therapies

Research output: Contribution to conferencePosterpeer-review

Original languageEnglish
Publication statusPublished - 18 Sep 2018

Cite this